Quattro Financial Advisors LLC Has $282,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Quattro Financial Advisors LLC boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 330.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,300 shares of the company’s stock after buying an additional 3,300 shares during the period. Quattro Financial Advisors LLC’s holdings in AstraZeneca were worth $282,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. McClarren Financial Advisors Inc. raised its holdings in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares during the period. Capital Performance Advisors LLP acquired a new stake in AstraZeneca during the 3rd quarter valued at $28,000. Albion Financial Group UT lifted its holdings in shares of AstraZeneca by 68.9% in the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after purchasing an additional 248 shares in the last quarter. Groupama Asset Managment boosted its position in shares of AstraZeneca by 22.9% in the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after buying an additional 101,225 shares during the period. Finally, Ashton Thomas Securities LLC purchased a new position in shares of AstraZeneca during the third quarter valued at $45,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

Shares of AZN stock opened at $71.99 on Friday. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The stock’s 50-day moving average is $67.38 and its two-hundred day moving average is $73.69. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The firm has a market cap of $223.25 billion, a P/E ratio of 31.85, a PEG ratio of 1.20 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.55%. Analysts predict that AstraZeneca PLC will post 4.66 earnings per share for the current fiscal year.

AstraZeneca Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Monday, March 24th. Investors of record on Friday, February 21st will be paid a $1.03 dividend. This represents a dividend yield of 2%. The ex-dividend date is Friday, February 21st. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.49. AstraZeneca’s payout ratio is presently 43.36%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on AZN shares. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.